Evaluation of clinical responses following long-term infusion of anti-GD2 antibody ch14.18/CHO in high-risk neuroblastoma patients

Purpose: GD2 is highly expressed in neuroblastoma (NB) and specifically recognized by antibody ch14.18/CHO. Immunotherapy with bolus infusion of ch14.18 in combination with cytokines effectively prolonged survival associated with substancial toxicity. Therefore, we piloted a treatment using continuous infusion of ch14.18 and report first results of clinical responses. Methodes and Marterials: Clinical response was assessed by mIBG, MRI/CT, bone marrow- and catecholamine- analysis before, after 3 and after 5/6 cycles of immunotherapy. Results: 41/37 pilot patients received up to 6 cycles of 6 × 106 IU/m2 s.c. IL-…